Ueno M, Miyagawa I, Nakano K, et al. - This study was undertaken to investigate the efficacy and safety of mepolizumab (MPZ) (300 mg) for relapsing/refractory eosinophilic granulomatosis with polyangiitis (EGPA) resistant to corticosteroids (CS) for 1 year in real-world settings. Mepolizumab (300 mg) was administered to 16 patients with relapsing/refractory EGPA resistant to CS (Post-MPZ). Data were obtained from the same patients for the 12 months before the administration of MPZ (Pre-MPZ). The results of this study exhibited that MPZ is effective and safe for EGPA. Moreover, MPZ reduces disease activity, increases remission rate, and has a CS-sparing effect.